|Year : 2022 | Volume
| Issue : 6 | Page : 267-273
The use of beta-blockers before major trauma and posttrauma outcome: A nationwide population-based study
Jen-Chun Wang1, Wu-Chien Chien2, Chi-Hsiang Chung2, Po-Chuan Chen3, Chin-Li Chen4, Shih-Hung Tsai5
1 Department of Emergency Medicine, Tri-Service General Hospital, National Defense Medical Center; Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei 112, Taiwan
2 Department of Medical Research, Tri-Service General Hospital, National Defense Medical Center, Taipei 112; School of Public Health, National Defense Medical Center; Taiwanese Injury Prevention and Safety Promotion Association, Taipei, Taiwan
3 Department of Emergency Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 112, Taiwan
4 Division of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
5 Department of Emergency Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 112; Department of Physiology and Biophysics, Graduate Institute of Physiology, National Defense Medical Center, Taipei, Taiwan
|Date of Submission||19-Jul-2021|
|Date of Decision||12-Oct-2021|
|Date of Acceptance||08-Nov-2021|
|Date of Web Publication||21-Jan-2022|
Prof. Shih-Hung Tsai
Department of Emergency Medicine, National Defense Medical Center, Tri-Service General Hospital, No. 325, Sector 2, Cheng-Kung Road, Neihu Dist., Taipei City 11490
Prof. Wu-Chien Chien
Department of Medical Research, National Defense Medical Center, Tri-Service General Hospital, No. 325, Sector 2, Cheng-Kung Road, Neihu Dist., Taipei City 11490
Source of Support: None, Conflict of Interest: None
Background: Beta-blockers are widely used for the treatment of arrhythmia, hypertension, and congestive heart failure. Major trauma causes significant blood loss and subsequent tachycardia and hypotension. Although beta-blockers may induce negative compensatory sympathetic responses to hemorrhagic shock, the effects of beta-blocker use before major trauma on posttrauma outcomes are controversial. Aim: We examined the association between the use of beta-blockers before major trauma and posttrauma outcomes using a nationwide population-based database. Methods: The data for this nationwide population-based retrospective cohort study were obtained from the National Health Insurance Research Database in Taiwan. A total of 2245 beta-blocker users were assigned to the study cohort, and another 8980 patients matched for age, sex, comorbidity, and medication use by inverse probability of treatment weighting formed the comparison cohort. The major outcome assessed was all-cause mortality during a 30-day follow-up period in major trauma patients with or without pretrauma beta-blocker use. Results: Our study included 2245 patients who used beta-blockers before major trauma. Individuals who used beta-blockers did not have a significantly higher cumulative risk of mortality than individuals who did not use beta-blockers (beta-blockers users: 17.19%, nonbeta-blockers users: 16.70%, P = 0.662). Conclusion: Pretrauma beta-blocker users did not have a higher mortality rate after a major trauma even after adjusting for several comorbidities and medications in a nationwide population database.
Keywords: Beta-blocker, trauma, National Health Insurance Research Database
|How to cite this article:|
Wang JC, Chien WC, Chung CH, Chen PC, Chen CL, Tsai SH. The use of beta-blockers before major trauma and posttrauma outcome: A nationwide population-based study. J Med Sci 2022;42:267-73
|How to cite this URL:|
Wang JC, Chien WC, Chung CH, Chen PC, Chen CL, Tsai SH. The use of beta-blockers before major trauma and posttrauma outcome: A nationwide population-based study. J Med Sci [serial online] 2022 [cited 2022 Dec 3];42:267-73. Available from: https://www.jmedscindmc.com/text.asp?2022/42/6/267/336233
Strengths and limitations of this study
- The strength of our study is its population-based cohort design. We excluded confounding factors, including comorbidities, from our study
- We controlled for potential disease-associated confounders to the utmost extent possible, but unmeasured or unknown confounders may exist in our findings
- The NHIRD did not provide detailed information on laboratory results or lifestyle factors of the patients
- Our results are limited to human data. Mechanistic and animal studies are required for further clarification.
| Introduction|| |
Beta-blockers are competitive antagonists that block the receptor sites for the endogenous catecholamines epinephrine and norepinephrine on adrenergic beta receptors of the sympathetic nervous system. Beta-blockers are generally used to treat arrhythmia. Although these agents are not used as first-line therapy, they are used to treat hypertension.,,
Uncontrolled hemorrhage is a leading cause of death in multiple trauma patients. The training program of the Advanced Trauma Life Support, the American College of Surgeons defined four classes of hypovolemic shock by the estimated blood loss using variations in heart rate, systolic blood pressure, and mental status. Therefore, the initial assessment of heart rate and blood pressure is an important step in evaluating the severity of the trauma, and it is one tool to help clinical physicians make rapid therapeutic decisions. Blockade of compensatory sympathetic activation to hypotension may have detrimental effects on hemodynamics.
The effects of beta-blocker use on injury victims are controversial. A few studies showed that pretrauma beta-blocker administration did not produce a hemodynamic response., However, some studies indicated that beta-blocker exposure improved clinical outcomes.,
To determine whether associations exist between pretrauma beta-blocker use and the clinical outcome of major trauma victims, we performed this exploratory study using the National Health Insurance Research Database (NHIRD) to evaluate the effects of beta-blocker use before major trauma on posttrauma outcomes.
| Materials and Methods|| |
The National Health Insurance (NHI) Program was launched in Taiwan in 1995. The NHI includes more than 99% of the entire Taiwanese population (more than 23 million beneficiaries). The NHIRD contains data on birthdate, sex, dates of admission and discharge, International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) diagnostic and procedure codes (up to five each), and outcomes. All information to identify patients is encrypted. The NHI Administration randomly reviews the medical records periodically to verify the accuracy of the diagnoses, and the accuracy of the diagnoses of major diseases in the NHIRD, such as acute coronary syndrome and stroke, was validated in previous studies. The data we used were from a subset of the NHIRD called the Longitudinal Health Insurance Database 2005 (LHID 2005). The LHID 2005 contains information on the medical service utilization of approximately two million randomly selected beneficiaries, which represents approximately 8% of the population in Taiwan in 2005. Data from 2000 to 2015 were extracted from the NHIRD. Injury events were identified from the Registry of Catastrophic Illness Patient Database, a subset of the NHIRD. Patients who were newly diagnosed with major trauma (injury severe score ≥16) can apply for a catastrophic illness certificate issued by the government, which allowed tracing. A panel of specialists and experts on the specific disease reviewed the medical records and imaging results before issuing a catastrophic illness certificate. This study was performed in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki). The Institutional Review Board of Tri-Service General Hospital at the National Defense Medical Center in Taipei, Taiwan approved this study (TSGHIRB No. 1-105-05-142), which waived the need to obtain individual consent because all of the identifying data were encrypted.
This study involved study and comparison cohorts. We selected adult patients aged ≥20 years who were newly diagnosed with traumatic injury (ICD-9-CM N800-999) and were followed up between 2000 and 2015. Inclusion criteria included patients who had an ISS higher than 16 and received a beta-blocker prescription at least twice in the 3 months before the trauma. We excluded patients who were diagnosed with major trauma before the index date. Patients who were lost to follow-up or whose sex was not known were also excluded from the study. The date of the major trauma diagnosis was used as the index date. Control candidate sampling comparisons were selected from individuals in the LHID 2005 who did not use beta-blockers during the 3 months before the index date. The patients and control cohorts were selected using 1:4 inverse probability of treatment weighting matching according to the following baseline variables: age; sex; comorbidities, including hypertension (ICD-9-CM 401–405), DM (ICD-9-CM 250), cardiac dysrhythmias (ICD-9-CM 427), ischemic heart disease (ICD-9-CM 410–414), heart failure (ICD-9-CM 428), asthma (ICD-9-CM 493), COPD (ICD-9-CM 490–496), obesity (ICD-9-CM 278), and chronic kidney disease (ICD-9-CM 582–589); and medication history, including digoxin, warfarin, and platelet aggregation inhibitors.
All statistical analyses were performed using SPSS software, version 22 (SPSS Inc., Chicago, IL, USA). The clinical characteristics of the patients enrolled in the study are expressed as numbers. Categorical variables are presented as percentages and were compared using Fisher's exact and Chi-squared tests. Continuous variables are presented as the means and standard deviations and were compared using t-tests. The primary goal of the study was to determine whether the use of beta-blockers was associated with all-cause mortality, intensive care unit (ICU) length of stay, and the need for blood transfusion within a 30-day follow-up period after major trauma. Associations between time-to-event outcomes (prognoses) and clinical characteristics were examined using the Kaplan-Meier method and multivariate Cox regression analysis with stepwise selection. The results are presented as adjusted hazard ratios (HRs) with the corresponding 95% confidence intervals. The Omnibus value of Cox regression of this study was <0.001. Statistical significance was indicated by P < 0.05.
Patients and public involvement
Patients and the public were not involved in the design or planning of the study.
| Results|| |
Among the 1,936,512 patients in the LHID 2005 from the NHIRD, 4241 beta-blocker users were diagnosed with major trauma. A total of 2245 patients were assigned to the study cohort, and another 2245 age-, sex-, comorbidity- and medication-matched patients formed the comparison cohort [Figure 1]. There were no significant differences in sex, age, comorbidities, or the number of medical follow-up visits between the groups that did and did not use beta-blockers after matching [Table 1].
Compared with patients who did not use beta-blockers, patients who used beta-blockers did not have a significantly higher cumulative risk of all-cause mortality after the index date [log-rank test P = 0.724, [Figure 2]. At the end of the 30-day follow-up period, no significant differences in all-cause mortality (17.19% vs. 16.70%, P = 0.662), ICU admission (79.11% vs. 78.26%, P = 0.489), ICU days (7.33 ± 3.55 vs. 7.31 ± 3.53, P = 0.850), hospitalization duration (7.89 ± 3.69 vs. 7.84 ± 3.65, P = 0.648) or the need for blood transfusion (42.05% vs. 41.69%, P = 0.809) were observed in patients who did or did not use beta-blockers [Table 2]. The data were stratified by age and the presence of a head injury. Among head injury patients, beta-blocker users had a higher incidence of admission to the ICU than non-users (38.91 vs. 38.73 per 100,000 person-days, adjusted HR = 1.124, P = 0.009). Among patients older than 65 years with head injuries, beta-blocker users had a higher rate of blood transfusion than nonusers [Table 3]. The data were also stratified by the medication possession ratio (MPR). Among the patients who have an MPR greater than 80%, 40%–80%, and below 40%, there was no significant difference in the major outcome [Supplementary Table 1]. The sensitivity test revealed that there is no significant difference in major outcomes between matching ratios [Supplemental Table 2]. Beta-blockers were divided into nonselective and selective for subgroup analysis. No significant difference was found between subgroups [Supplemental Table 3].
|Table 2: Incidence rates of outcomes and other characteristics in the enrolled study participants at the end of the 30 days follow-up period|
Click here to view
|Table 3: Factors associated with outcomes according to the Cox regression model|
Click here to view
| Discussion|| |
This population-based study with a nationwide dataset revealed that the prior use of beta-blockers did not result in a significantly higher 30-day mortality rate in patients who sustained major trauma, even after adjusting for age, sex, comorbidities, and medications.
The inflammatory response begins a few minutes or hours after a major trauma event. Systemic inflammatory response syndrome, adult respiratory distress syndrome, and multiple organ failure following a trauma event affect trauma-related mortality. Beta-blocker administration decreases the concentrations of proinflammatory cytokines, such as interleukin-6. Stress-related activation of the sympathetic nervous system results in the increased secretion and circulation of catecholamines. Sustained and excessive adrenergic activity is associated with increased mortality. The use of beta-blockers blunts the hyperadrenergic state and decreases mortality. Major trauma causes massive blood loss and hypovolemia. Multisystem injuries result in critical cardiac stress. Acute myocardial infarction occurs due to increased myocardial oxygen demand or reduced supply in the absence of acute atherothrombotic plaque disruption. For example, hypovolemic shock is called type 2 myocardial infarction. Some studies observed that beta-blockers reduced the odds of death at 2 years in patients with type 2 myocardial infarction who used beta-blockers compared to the odds in those who did not use these agents. Trauma-related wound infection, surgical wound infection, or hospital-acquired infection affect mortality. A previous prescription of beta-blockers is associated with reduced mortality in patients who were hospitalized in the ICU for sepsis.
Beta-blockers lower the systemic blood pressure and cerebral perfusion pressure, and there is concern about their use in patients with hypovolemic shock or head injury. Some studies described that preinjury beta-blocker use was associated with a higher mortality rate. Beta-blockers may blunt the response to shock and decrease the ability to compensate for cardiac output after major trauma-related shock., Another study showed that the pretrauma use of cardiac-specific agents led to a higher mortality rate. However, the use of a combination of beta-blockers and other cardiac-specific agents, such as calcium channel blockers and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, before trauma does not inhibit the hemodynamic response in trauma cases.
Abnormal heart rate and blood pressure are signs of hypovolemia, and blood transfusion is generally needed when fluid resuscitation does not reverse it. Previous studies of the hemodynamic effect of the preinjury use of beta-blockers produced controversial results. Our study found no difference between beta-blocker users and nonusers in the need for blood transfusion after major trauma.
This study is the first study to investigate the association between the preinjury use of beta-blockers and outcomes after major trauma in an Asian population. The strength of this study is that it was a population-based study. Complete medical and medication use records of patients were registered in the NHIRD. Comorbidities and medications were matched between the beta-blocker users and nonusers in this study. Compared to previous studies on the effect of beta-blockers on brain trauma patients, our study included trauma patients who have an ISS = 16 or higher. Patients in our study were diverse since major trauma patients usually do not have only single organ injury. The disadvantage of this study compared to the previous studies described above is that the NHIRD did not provide detailed information on vital signs, such as heart rate and blood pressure, of trauma victims of this study. Vital signs would provide some important information, such as hemodynamic status. Cushing triads, a clinical sign of increased intracranial pressure, are also represented by vital signs.
This study was a retrospective cohort study. Although we extensively adjusted our results using multivariate logistic regression models, residual limitations may exist. The NHIRD registry does not provide detailed information on the severity of the injury, exact ISS scores, precise injury site of specific organs, health-related lifestyle factors, heart rate, blood pressure, imaging results or laboratory results, and these conditions may be confounding factors. The NHIRD registry only provides the prescriptions patients obtained, and there is no information on patient compliance with the prescription.
| Conclusion|| |
We observed that beta-blocker users did not have a higher all-cause mortality rate than non-users, even after adjusting for several comorbidities and medications in a nationwide population database.
We are grateful for providing information from Prof. Chih-Yuan Lin and Dr. Yi-Da Tsai.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Grandi E, Ripplinger CM. Antiarrhythmic mechanisms of beta blocker therapy. Pharmacol Res 2019;146:104274.
Mann SJ. Redefining beta-blocker use in hypertension: Selecting the right beta-blocker and the right patient. J Am Soc Hypertens 2017;11:54-65.
Wong GW, Boyda HN, Wright JM. Blood pressure lowering efficacy of partial agonist beta blocker monotherapy for primary hypertension. Cochrane Database Syst Rev 2014;2014:CD007450.
Evans JA, van Wessem KJ, McDougall D, Lee KA, Lyons T, Balogh ZJ. Epidemiology of traumatic deaths: Comprehensive population-based assessment. World J Surg 2010;34:158-63.
American College of Surgeons. ATLS: Advanced Trauma Life Support for Doctors: Student Course Manual. Chicago, IL: American College of Surgeons; 2008.
Evans DC, Khoo KM, Radulescu A, Cook CH, Gerlach AT, Papadimos TJ, et al
. Pre-injury beta blocker use does not affect the hyperdynamic response in older trauma patients. J Emerg Trauma Shock 2014;7:305-9.
] [Full text]
Havens JM, Carter C, Gu X, Rogers SO Jr. Preinjury beta blocker usage does not affect the heart rate response to initial trauma resuscitation. Int J Surg 2012;10:518-21.
Riordan WP Jr., Cotton BA, Norris PR, Waitman LR, Jenkins JM, Morris JA Jr. Beta-blocker exposure in patients with severe Traumatic Brain Injury (TBI) and cardiac uncoupling. J Trauma 2007;63:503-10.
Cotton BA, Snodgrass KB, Fleming SB, Carpenter RO, Kemp CD, Arbogast PG, et al.
Beta-blocker exposure is associated with improved survival after severe traumatic brain injury. J Trauma 2007;62:26-33.
Cheng CL, Kao YH, Lin SJ, Lee CH, Lai ML. Validation of the National Health Insurance Research database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf 2011;20:236-42.
Donnelly SC, Robertson C. Mediators, mechanisms and mortality in major trauma. Resuscitation 1994;28:87-92.
Friese RS, Barber R, McBride D, Bender J, Gentilello LM. Could beta blockade improve outcome after injury by modulating inflammatory profiles? J Trauma 2008;64:1061-8.
Desborough JP. The stress response to trauma and surgery. Br J Anaesth 2000;85:109-17.
Johansson PI, Stensballe J, Rasmussen LS, Ostrowski SR. High circulating adrenaline levels at admission predict increased mortality after trauma. J Trauma Acute Care Surg 2012;72:428-36.
Sandoval Y, Smith SW, Sexter A, Thordsen SE, Bruen CA, Carlson MD, et al.
Type 1 and 2 myocardial infarction and myocardial injury: Clinical transition to high-sensitivity cardiac troponin I. Am J Med 2017;130:1431-9.e4.
Macchia A, Romero M, Comignani PD, Mariani J, D'Ettorre A, Prini N, et al.
Previous prescription of β-blockers is associated with reduced mortality among patients hospitalized in Intensive Care Units for sepsis. Crit Care Med 2012;40:2768-72.
Ferraris VA, Ferraris SP, Saha SP. The relationship between mortality and preexisting cardiac disease in 5,971 trauma patients. J Trauma 2010;69:645-52.
Neideen T, Lam M, Brasel KJ. Preinjury beta blockers are associated with increased mortality in geriatric trauma patients. J Trauma 2008;65:1016-20.
[Figure 1], [Figure 2]
[Table 1], [Table 2], [Table 3]